Policy & Regulation
Cyxone's first-in-human MS study of T20K to be concluded in the second half of 2019
15 July 2019 -

Swedish biotech company Cyxone (publ.) said on Friday that it has dosed the healthy male volunteer under its first-in-human, clinical phase I, trial of T20K for the treatment of multiple sclerosis (MS).

The company added that the recruitment and screening of healthy male volunteers for its first-in-human trial with T20K was initiated in June, following the approval from the relevant authorities in the Netherlands. The clinical phase I study with its drug candidate T20K is expected to be concluded during the second half of 2019.

In conjunction, the study aims to evaluate the safety and tolerability of T20K in humans by assessing the level of T20K in the blood after administering one or two dose-levels of the substance. The first cohort of healthy male volunteers have received their first dose of T20K through infusion, which will be followed by potentially one additional cohort receiving two doses if needed. Each cohort comprise of eight healthy male volunteers.

According to the company, T20K is in development as a novel form of multiple sclerosis (MS) treatment with prophylactic properties. Results from preclinical studies demonstrate that the candidate could be used to mitigate or even prevent MS episodes and potentially even delay the disease progression. The candidate has demonstrated a low toxicity level and could, due to its favorable absorption and distribution in the body, be administrated at low doses on a bi-weekly or even monthly basis.

Login
Username:

Password: